Neuronal TGase (TG6) ELISA

ZediXclusive TG6-ab ELISA (IgG)

Neuronal transglutaminase (TG6) ELISA IgG

1 Kit/96 wells 520 € available

Art. No. E104
Background info The TG6-ab ELISA (IgG) kit with the Zedira product number E104 is the revised version of kit TG6-ab ELISA (IgG) with the product number E004.

Autoantibodies directed against neuronal transglutaminase (TG6) may occur in the sera of patients suffering from neurological disorders like e.g. ataxia, neuropathy, cerebral pulsy or stiffperson syndrome.
Autoantibodies to TG6 can be found in addition to TG2-autoantibodies in celiac patients, but were also found in TG2-autoantibody negative sera and in sera from patients without enteropathy (non-celiac patients). Therefore antibodies to TG6 may develop independent from celiac disease.
Assay principle The wells of the solid phase are coated with TG6.
1st reaction: TG6-specific antibodies present in the sample bind to the immobilised antigen, forming the antigen-antibody complex.
2nd reaction: A second antibody, directed at human IgG antibodies and labeled with horse-radish peroxidase (HRP), binds to the complex.
3rd reaction: The enzyme-labelled complex converts a substrate into a blue product. Samples containing IgG antibodies against TG6 develop the blue colour, whereas samples without these antibodies remain colourless.
Intended use The present Enzyme-Linked Immuno Sorbent Assay (ELISA) is intended for the quantitative or qualitative determination of IgG antibodies in human serum, directed against TG6. The immobilised antigen is a highly purified preparation of human recombinant TG6. The test is fast (incubation time 30 / 30 / 30 minutes) and flexible (divisible solid phase, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control check the assay performance.
Storage Store kit at 2 - 8°C. It is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date.
  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland